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Sir,
I want to comment on a review by Raguz and Yagu ¨e (2008) in a
recent issue of Br J Cancer. The authors state correctly ‘although
traditionally associated with the last stages of disease, recent
findings with minimally transformed pre-tumourigenic primary
human cells indicate that the ability to generate drug resistance
arises early during the tumourigenic process and before the full
transformation’. Here I try to explain why tumour cells can be
resistant at the pre-tumourigenic stage and why in later stages of
the disease.
Cancer cells may be intrinsically resistant because (i) as
mentioned by the authors, the cancer stem cell hypothesis states
that many, if not all, cancers contain a minority of stem cells. Stem
cells are resistant to apoptosis, exhibit enhanced DNA repair
activities and express membrane-bound ATP-binding cassette
transporter (ABC) transporters that make them resistant to
exogenous poisons (and chemotherapeutic agents) (Sakariassen
et al, 2007; Styczynski and Drewa, 2007; Wicha et al, 2006). (ii) one
can assume that a tumour exhibits similar sensitivity (or
resistance) as the tissue from which the tumour originates. If the
normal tissue and the tumour exhibit similar sensitivity, there is
no therapeutic window, and at drug concentrations at which the
tumour responds, normal tissue is damaged. In this case, the
tumour resistance also exists already in minimally transformed
pre-tumourigenic cells (intrinsic or inherent resistance). There-
fore, tumour cells that respond to treatment must be more
sensitive than the untransformed tissue from which the tumour
cells originate. Thus one important question arises: what makes a
tumour more sensitive than the tissue from which it originates, or
in other words, what enables successful treatment of a certain
percentage of tumours? One reason is that the tumour cells exhibit
a different trait. For example, chronic myelogenous leukemia
(CML) cells exhibit higher responsiveness to Bcr/Abl inhibitors,
because Bcr/Abl is only expressed in tumour cells and drives
tumour proliferation. The classical explanation for the success of
traditional chemotherapy is that tumour cells are more sensitive
because of their higher proliferation rate compared with most
normal cells. However, there are several arguments against it. The
first one is that if faster proliferation is the reason for sensitivity
of tumour cells, at least all rapidly proliferating tumours should
be sensitive to all or many of the traditional chemo-
therapeutic drugs. As we know, most tumours are only sensitive
to one or several of the many antitumour drugs available. A second
argument is that not all tumour cells are proliferating faster than
non-transformed cells. For example, in the gastrointestinal tract,
there are zones of fast proliferation of normal cells, and tumours
derived from these cells need years to develop.
Therefore, at the starting point of tumourigenesis are stem
cells or normal non-transformed cells, which exhibit a certain
sensitivity. Let us assume that from these cells, tumour cells of the
same sensitivity are generated. These tumour cells are classified as
resistant because in case of such a tumour no therapeutic window
is to be found. Thus, most of the tumours are resistant against
most of the antitumour drugs. However, in certain tumours a
majority of cells can be unusually sensitive to one or several
anticancer drugs and, therefore, respond to therapy. These cells
may become more sensitive to targeted therapy (by a new target)
or to one or several of the traditional anticancer drugs (in many
cases by unknown mechanisms) during tumourigenesis or as
tumour cells. Upon treatment (i) sensitive cells are eliminated
and the intrinsic resistant tumour cells survive and proliferate.
(ii) Tumours can acquire resistance to the one or several drugs, to
which they were sensitive and respond, in later stages by increased
expression of ABC transporters, cytochrome 450, reduction of
apoptosis, etc. This model can explain why resistance is to be
found, on one side, in minimally transformed pre-tumourigenic
cells, but on the other, it also can arise at later stages of the disease.
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